Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with anti-PD-1 and beyond - - Roche sponsoring randomi...

Related Keywords

United States ,Japan ,Australia ,China ,France ,Florida ,Sanjin ,Japan General ,Suzhou ,Jiangsu ,Singapore ,Orlando ,American ,Powerbody Tces ,Peter Luo ,Development Rd Expenses ,Twitter ,Exchange Commission ,American Association For Cancer Research ,Linkedin ,Nasdaq ,European Union ,Biovie Inc ,Gustave Roussy Cancer Center ,Drug Development Department ,Adagene Inc ,Food Drug Administration Project Optimus ,Dynamic Precision Library ,Chief Executive Officer ,American Association ,Cancer Research ,Drug Administration ,Project Optimus ,Dragon Boat Biopharmaceutical ,Greater China ,Professor Aur ,Strategic Advisory ,Professor Marabelle ,Chief Strategy Officer ,Cash Equivalents ,Consolidated Statements ,Year Ended December ,